Diabetes treatment is constantly evolving, with new therapeutic options developing to improve patient outcomes. Recent investigations have focused on GLP-1 and GIP receptor agonists, a class of drugs that mimic the actions of naturally occurring hormones involved in bloodlevel regulation. These novel agents demonstrate promising results in improvin

Retaglutide and tirzepatide represent cutting-edge type of medications known as dual GLP-1 and GIP agonists. These agents regulate both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that perform a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones